Sequenom Inc (SQNM) 2.40 $SQNM
LabCorp's Takeover of Sequenom Wins Antitrust Clearance
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 4:26PM CDT
LabCorp (LH) recently got the antitrust review clearance for its previously announced acquisition of Sequenom.
DSCI: 4.72 (-0.12), SQNM: 2.40 (unch), ALGN: 95.78 (+2.02), LH: 137.71 (+1.58)
LabCorp's Acquisition of Sequenom Clears Antitrust Review
BusinessWire - Tue Aug 23, 7:45AM CDT
Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE:LH) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, applicable to the acquisition of Sequenom, Inc. ("Sequenom"
by LabCorp has expired. As previously announced, LabCorp and Savoy Acquisition Corp., its direct wholly owned subsidiary ("Purchaser", commenced a tender offer on August 9, 2016, for all of the outstanding shares of common stock of Sequenom, including the associated preferred stock purchase rights, for $2.40 net to the seller in cash, without interest thereon and subject to applicable withholding taxes. The expiration of the waiting period under the HSR Act satisfies one of the conditions necessary for the consummation of the pending acquisition. The tender offer and any withdrawal rights are scheduled to expire at 12:01 a.m., Eastern Time, on Wednesday, September 7, 2016, unless the tender offer is extended. Consummation of the tender offer remains subject to other customary closing conditions, including satisfaction of the minimum tender condition under the agreement and plan of merger entered into by LabCorp, Purchaser and Sequenom on July 26, 2016.
SQNM: 2.40 (unch), LH: 137.71 (+1.58)
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Sequenom, Inc. (SQNM)
GlobeNewswire - Mon Aug 22, 11:35AM CDT
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Sequenom, Inc. ("Sequenom" or the "Company" (Nasdaq:SQNM) in the United States District Court for the Southern District of California on behalf of current stock holders of Sequenom, seeking to pursue remedies under the Securities Exchange Act of 1934 (the "Exchange Act".
SQNM: 2.40 (unch)
LabCorp Commences Cash Tender Offer for All Outstanding Shares of Sequenom, Inc.
BusinessWire - Tue Aug 09, 7:00AM CDT
Laboratory Corporation of America(R) Holdings (NYSE: LH) today announced the commencement of its cash tender offer for all outstanding shares of the common stock of Sequenom, Inc. (NASDAQ: SQNM) for $2.40 per share. The tender offer is being made by Savoy Acquisition Corp., a wholly owned subsidiary of LabCorp, pursuant to an offer to purchase, dated August 9, 2016. LabCorp and Sequenom previously announced that they entered into an agreement and plan of merger, dated as of July 26, 2016, for LabCorp to acquire Sequenom.
SQNM: 2.40 (unch), LH: 137.71 (+1.58)
SEQUENOM SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Sequenom, Inc. (SQNM) Over the Proposed Sale of the Company to Laboratory Corporation of America Holdings
PR Newswire - Mon Aug 01, 4:01PM CDT
Nadeem Faruqi, founding partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Sequenom, Inc. ("Sequenom" or the "Company" (NASDAQ: SQNM) for potential breaches of fiduciary duties in connection with the sale of the Company to Laboratory Corporation of America Holdings for approximately $371 million.
SQNM: 2.40 (unch), LH: 137.71 (+1.58)
Can The Uptrend Continue for Sequenom (SQNM)?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 5:30AM CDT
Investors certainly have to be happy with Sequenom, Inc. (SQNM) and its short term performance
SQNM: 2.40 (unch)
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Sequenom, Inc. And Encourages Investors To Contact The Firm For Additional Information
BusinessWire - Thu Jul 28, 12:51PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Sequenom, Inc. (NASDAQ: SQNM) ("Sequenom" or the "Company" relating to the proposed buyout of Sequenom by Laboratory Corporation of America Holdings.
SQNM: 2.40 (unch)
Sequenom Announces Cancellation of Second Quarter 2016 Results Conference Call
PR Newswire - Thu Jul 28, 6:00AM CDT
Sequenom, Inc., (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, announced on July 27, 2016 that it entered into a definitive agreement and plan of merger with Laboratory Corporation of America® Holdings (LabCorp®) under which LabCorp would acquire all of the outstanding shares of Seqeunom in a cash tender offer. In light of this announcement, Sequenom has cancelled its second quarter 2016 earnings conference call scheduled to take place on Wednesday, August 3, 2016 at 5:00 p.m. ET (2:00 p.m. PT).
SQNM: 2.40 (unch)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of Sequenom, Inc. -SQNM
PR Newswire - Wed Jul 27, 8:36PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Sequenom, Inc. ("Sequenom" or "the Company" (Nasdaq- SQNM-News) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Laboratory Corporation of America Holdings ("Lab Corp.".
SQNM: 2.40 (unch), LH: 137.71 (+1.58)
LabCorp (LH) Tops Q2 Earnings, View Up, to Buy Sequenom
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 12:16PM CDT
LabCorp (LH) reported a solid second quarter 2016 with adjusted earnings per share (EPS) of $2.31, up 10.5% from the year-ago quarter.
SQNM: 2.40 (unch), BCR: 221.21 (-0.29), LH: 137.71 (+1.58), COO: 185.92 (+0.55)
Sequenom Files Patent Infringement Lawsuit in Australia
PR Newswire - Tue Jun 07, 7:30AM CDT
Sequenom, Inc., (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced that it filed a patent infringement lawsuit in Australia. The patent relates to the detection of cell-free fetal DNA for non-invasive prenatal testing (NIPT).
SQNM: 2.40 (unch)
Sequenom to Present at Jefferies Global Healthcare Conference
PR Newswire - Thu Jun 02, 1:37PM CDT
Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced the Company's participation at the Jefferies 2016 Global Healthcare Conference in New York, NY on June 10, 2016.
SQNM: 2.40 (unch)
AWS Morning Technical Breakdown Highlights: bluebird bio, Nektar Therapeutics, Sequenom, and Tesaro
ACCESSWIRE - Mon May 23, 8:18AM CDT
LONDON, UK / ACCESSWIRE / May 23, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include bluebird bio, Nektar Therapeutics, Sequenom, and Tesaro.
BLUE: 49.05 (-0.28), SQNM: 2.40 (unch), TSRO: 84.87 (+0.52), NKTR: 18.45 (+0.34)
Sequenom, Inc. Reports First Quarter 2016 Results
PR Newswire - Wed May 04, 3:03PM CDT
Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today reported total revenues of $27.6 million, total accessioned units of 46,400, and a net loss of $13.4 million, or $0.11 per basic and diluted share, for the first quarter of 2016.
SQNM: 2.40 (unch)
Sequenom Announces In-Network Contracts with Anthem Blue Cross and Blue Shield Plans for Georgia, Indiana, Kentucky, Missouri, Ohio, Virginia and Wisconsin
PR Newswire - Tue May 03, 6:01PM CDT
Sequenom, Inc., (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced that it has entered into agreements with Blue Cross and Blue Shield of Georgia, Inc. (effective 4/11/16), Anthem Blue Cross and Blue Shield Health Plans for Indiana, Kentucky, Missouri, Ohio and Wisconsin (effective 5/15), and Anthem Blue Cross and Blue Shield in Virginia (effective 5/23/16).
SQNM: 2.40 (unch)
Sequenom Completes Consolidation of North Carolina Operations
PR Newswire - Tue Apr 19, 3:02PM CDT
Sequenom, Inc., (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced the completion of the previously-announced consolidation of Sequenom Laboratories(TM) North Carolina operations into its San Diego laboratory facility.
SQNM: 2.40 (unch)
Sequenom Strengthens Executive Team with New Vice President of Sales
PR Newswire - Tue Apr 12, 3:03PM CDT
Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, is pleased to announce that Glenn Magnuson has joined the Company as Vice President of Sales, reporting to Rob Lozuk, Senior Vice President, Commercial Operations. Mr. Magnuson has more than 25 years of experience in implementing effective sales processes, strategically managing accounts and realizing the revenue potential of medical diagnostic devices.
SQNM: 2.40 (unch)
LabCorp's Takeover of Sequenom Wins Antitrust Clearance
Zacks Equity Research - Zacks Investment Research - Thu Aug 25, 4:26PM CDT
LabCorp (LH) recently got the antitrust review clearance for its previously announced acquisition of Sequenom.
DSCI: 4.72 (-0.12), SQNM: 2.40 (unch), ALGN: 95.78 (+2.02), LH: 137.71 (+1.58)
LabCorp's Acquisition of Sequenom Clears Antitrust Review
BusinessWire - Tue Aug 23, 7:45AM CDT
Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE:LH) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, applicable to the acquisition of Sequenom, Inc. ("Sequenom"
by LabCorp has expired. As previously announced, LabCorp and Savoy Acquisition Corp., its direct wholly owned subsidiary ("Purchaser", commenced a tender offer on August 9, 2016, for all of the outstanding shares of common stock of Sequenom, including the associated preferred stock purchase rights, for $2.40 net to the seller in cash, without interest thereon and subject to applicable withholding taxes. The expiration of the waiting period under the HSR Act satisfies one of the conditions necessary for the consummation of the pending acquisition. The tender offer and any withdrawal rights are scheduled to expire at 12:01 a.m., Eastern Time, on Wednesday, September 7, 2016, unless the tender offer is extended. Consummation of the tender offer remains subject to other customary closing conditions, including satisfaction of the minimum tender condition under the agreement and plan of merger entered into by LabCorp, Purchaser and Sequenom on July 26, 2016. SQNM: 2.40 (unch), LH: 137.71 (+1.58)
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Sequenom, Inc. (SQNM)
GlobeNewswire - Mon Aug 22, 11:35AM CDT
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Sequenom, Inc. ("Sequenom" or the "Company"
(Nasdaq:SQNM) in the United States District Court for the Southern District of California on behalf of current stock holders of Sequenom, seeking to pursue remedies under the Securities Exchange Act of 1934 (the "Exchange Act". SQNM: 2.40 (unch)
LabCorp Commences Cash Tender Offer for All Outstanding Shares of Sequenom, Inc.
BusinessWire - Tue Aug 09, 7:00AM CDT
Laboratory Corporation of America(R) Holdings (NYSE: LH) today announced the commencement of its cash tender offer for all outstanding shares of the common stock of Sequenom, Inc. (NASDAQ: SQNM) for $2.40 per share. The tender offer is being made by Savoy Acquisition Corp., a wholly owned subsidiary of LabCorp, pursuant to an offer to purchase, dated August 9, 2016. LabCorp and Sequenom previously announced that they entered into an agreement and plan of merger, dated as of July 26, 2016, for LabCorp to acquire Sequenom.
SQNM: 2.40 (unch), LH: 137.71 (+1.58)
SEQUENOM SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Sequenom, Inc. (SQNM) Over the Proposed Sale of the Company to Laboratory Corporation of America Holdings
PR Newswire - Mon Aug 01, 4:01PM CDT
Nadeem Faruqi, founding partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Sequenom, Inc. ("Sequenom" or the "Company"
(NASDAQ: SQNM) for potential breaches of fiduciary duties in connection with the sale of the Company to Laboratory Corporation of America Holdings for approximately $371 million. SQNM: 2.40 (unch), LH: 137.71 (+1.58)
Can The Uptrend Continue for Sequenom (SQNM)?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 5:30AM CDT
Investors certainly have to be happy with Sequenom, Inc. (SQNM) and its short term performance
SQNM: 2.40 (unch)
SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Sequenom, Inc. And Encourages Investors To Contact The Firm For Additional Information
BusinessWire - Thu Jul 28, 12:51PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Sequenom, Inc. (NASDAQ: SQNM) ("Sequenom" or the "Company"
relating to the proposed buyout of Sequenom by Laboratory Corporation of America Holdings. SQNM: 2.40 (unch)
Sequenom Announces Cancellation of Second Quarter 2016 Results Conference Call
PR Newswire - Thu Jul 28, 6:00AM CDT
Sequenom, Inc., (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, announced on July 27, 2016 that it entered into a definitive agreement and plan of merger with Laboratory Corporation of America® Holdings (LabCorp®) under which LabCorp would acquire all of the outstanding shares of Seqeunom in a cash tender offer. In light of this announcement, Sequenom has cancelled its second quarter 2016 earnings conference call scheduled to take place on Wednesday, August 3, 2016 at 5:00 p.m. ET (2:00 p.m. PT).
SQNM: 2.40 (unch)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of Sequenom, Inc. -SQNM
PR Newswire - Wed Jul 27, 8:36PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Sequenom, Inc. ("Sequenom" or "the Company"
(Nasdaq- SQNM-News) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Laboratory Corporation of America Holdings ("Lab Corp.". SQNM: 2.40 (unch), LH: 137.71 (+1.58)
LabCorp (LH) Tops Q2 Earnings, View Up, to Buy Sequenom
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 12:16PM CDT
LabCorp (LH) reported a solid second quarter 2016 with adjusted earnings per share (EPS) of $2.31, up 10.5% from the year-ago quarter.
SQNM: 2.40 (unch), BCR: 221.21 (-0.29), LH: 137.71 (+1.58), COO: 185.92 (+0.55)
Sequenom Files Patent Infringement Lawsuit in Australia
PR Newswire - Tue Jun 07, 7:30AM CDT
Sequenom, Inc., (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced that it filed a patent infringement lawsuit in Australia. The patent relates to the detection of cell-free fetal DNA for non-invasive prenatal testing (NIPT).
SQNM: 2.40 (unch)
Sequenom to Present at Jefferies Global Healthcare Conference
PR Newswire - Thu Jun 02, 1:37PM CDT
Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced the Company's participation at the Jefferies 2016 Global Healthcare Conference in New York, NY on June 10, 2016.
SQNM: 2.40 (unch)
AWS Morning Technical Breakdown Highlights: bluebird bio, Nektar Therapeutics, Sequenom, and Tesaro
ACCESSWIRE - Mon May 23, 8:18AM CDT
LONDON, UK / ACCESSWIRE / May 23, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include bluebird bio, Nektar Therapeutics, Sequenom, and Tesaro.
BLUE: 49.05 (-0.28), SQNM: 2.40 (unch), TSRO: 84.87 (+0.52), NKTR: 18.45 (+0.34)
Sequenom, Inc. Reports First Quarter 2016 Results
PR Newswire - Wed May 04, 3:03PM CDT
Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today reported total revenues of $27.6 million, total accessioned units of 46,400, and a net loss of $13.4 million, or $0.11 per basic and diluted share, for the first quarter of 2016.
SQNM: 2.40 (unch)
Sequenom Announces In-Network Contracts with Anthem Blue Cross and Blue Shield Plans for Georgia, Indiana, Kentucky, Missouri, Ohio, Virginia and Wisconsin
PR Newswire - Tue May 03, 6:01PM CDT
Sequenom, Inc., (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced that it has entered into agreements with Blue Cross and Blue Shield of Georgia, Inc. (effective 4/11/16), Anthem Blue Cross and Blue Shield Health Plans for Indiana, Kentucky, Missouri, Ohio and Wisconsin (effective 5/15), and Anthem Blue Cross and Blue Shield in Virginia (effective 5/23/16).
SQNM: 2.40 (unch)
Sequenom Completes Consolidation of North Carolina Operations
PR Newswire - Tue Apr 19, 3:02PM CDT
Sequenom, Inc., (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced the completion of the previously-announced consolidation of Sequenom Laboratories(TM) North Carolina operations into its San Diego laboratory facility.
SQNM: 2.40 (unch)
Sequenom Strengthens Executive Team with New Vice President of Sales
PR Newswire - Tue Apr 12, 3:03PM CDT
Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, is pleased to announce that Glenn Magnuson has joined the Company as Vice President of Sales, reporting to Rob Lozuk, Senior Vice President, Commercial Operations. Mr. Magnuson has more than 25 years of experience in implementing effective sales processes, strategically managing accounts and realizing the revenue potential of medical diagnostic devices.
SQNM: 2.40 (unch)
